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Recent studies have associated human metapneu-
movirus (HMPV) infection in children with respiratory dis-
ease of similar severity as respiratory syncytial virus (RSV)
infection. We studied 668 banked swab specimens (one
per admission) collected from a population-based,
prospective study of acute respiratory illness among inpa-
tient children from two U.S. cities. Specimens were tested
for HMPV, RSV, influenza, and parainfluenza viruses by
reverse transcription–polymerase chain reaction assays.
Twenty-six (3.9%) were positive for HMPV; 125 (18.7%) for
RSV; 45 (6.7%) for parainfluenza 1, 2, or 3; and 23 (3.4%)
for influenza. HMPV-positive children were significantly
older than RSV-positive children. HMPV-positive children
required medical intensive care and received supplemental
oxygen in similar frequencies to RSV-positive children.
Among children hospitalized with respiratory illness, the
incidence of HMPV infection was less than RSV, but clini-
cal disease severity mirrored that of RSV infection. Further
investigations to better characterize HMPV infection and its
clinical effect are needed.
H
uman metapneumovirus (HMPV) is a recently dis-
covered respiratory pathogen of the family
Paramyxoviridae  belonging to the same subfamily,
Pneumovirinae, as respiratory syncytial virus (RSV) (1,2).
HMPV was first recognized in the Netherlands in 2001 in
nasopharyngeal aspirate samples collected from children
over a 20-year period (1). It has since been identified in
Canada (3,4), Australia (5), the United Kingdom (6),
France (7), Hong Kong (8), and the United States (9).
Recent reports investigating HMPV have shown that
HMPV-infected children who are hospitalized with respi-
ratory illness frequently have clinical diagnoses of bron-
chiolitis and pneumonia, much like children infected with
RSV (1,4,5,7,10). Clinical symptoms from HMPV-infect-
ed children have included nonproductive cough, nasal con-
gestion, and wheezing (5,6,8,11). The most commonly
reported abnormality on chest radiography was bilateral
infiltrates, indicative of pneumonia (5,11). One child with
influenza-like illness seen in an outpatient clinic was
reported to have HMPV and negative cultures for influen-
za virus and RSV (6). 
A recent study in Hong Kong looked at HMPV infec-
tion by using a prospective, population-based design (8),
but no such studies on HMPV infection have been report-
ed that used U.S. data. We present results of such studies
and confirm the effect of HMPV infections on acute respi-
ratory illness (ARI) hospitalizations in children.
Methods 
Study Design
The design of the parent study has been described previ-
ously (12). The present study was conducted as part of the
New Vaccine Surveillance Network, a population-based
active surveillance network for vaccine-preventable dis-
eases related to new vaccines. The study samples were col-
lected at two hospitals in Rochester, New York and three
hospitals in Nashville, Tennessee; each cares for >95% of
children hospitalized in their respective counties (Monroe
County, New York and Davidson County, Tennessee). The
children from these two counties provide population-based
data. Rochester hospitals also contributed samples from
children who resided in six outlying counties. The data
from the outlying counties are not regarded as population-
based since those counties are also served by their outlying
hospitals. Samples were collected from August 2000
through September 2001 from children <5 years of age hos-
pitalized for ARI or ARI-related diagnoses. 
Combined nose and throat swab specimens from each
child were cultured at the study sites for influenza virus A
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had not yet been discovered at the beginning of the trial
and, therefore, was not investigated. Frozen aliquots of
each specimen were analyzed for the above viruses plus
HMPV by using reverse transcription–polymerase chain
reaction (RT-PCR) assays and GeneScan deoxyribonucleic
acid fragment analysis of PCR products. All viruses were
confirmed from a second aliquot of sample. A positive
virus culture or confirmed RT-PCR was considered a pos-
itive test for respiratory viruses other than HMPV. 
RT-PCR Process for HMPV 
The RT-PCR assays for HMPV were performed as
described previously (13). Briefly, RNAextracts were pre-
pared from 100 µL of specimen by using the automated
NucliSens extraction system (bioMérieux, Durham, NC).
Oligonucleotide primers used for RT-PCR were designed
to conserved regions of the HMPV nucleoprotein and
fusion protein genes, and one primer for each set was 5′-
end-labeled with fluorescein (6-FAM) to facilitate
GeneScan analysis. One-step amplification reactions were
performed by using the Access RT-PCR System (Promega
Corp., Madison, WI). HMPV-positive and -negative con-
trols containing a standardized viral RNA extract and
nuclease-free water, respectively, were included in each
assay. Amplification products were analyzed on an ABI
Prism 310 Genetic Analyzer (Applied Biosystems, Foster
City, CA) with GeneScan software (ver. 3.1.2).
Electropherograms were reviewed, and amplification
products identified within 2 nt of the expected size (195 nt
for nucleoprotein gene; 347 nt for the fusion protein gene)
were considered “preliminary” positives. Preliminary pos-
itives were then repeat-tested with a new extraction, when
an additional specimen aliquot was available. Because
viral culture for HMPV was unavailable, specimens were
designated “true” positives if the same amplification prod-
uct for both genes was identified on repeat testing of the
sample extract. 
Statistical Analysis
Epidemiologic data were analyzed by using Statistical
Analysis Software (SAS) version 8.0 (SAS Institute) and
EpiInfo 6.04d (Centers for Disease Control and
Prevention, Atlanta, Georgia). Statistical significance was
determined by using the chi-square test with α = 0.05. We
include data from the eight counties in all analyses in this
paper except for the population-based incidence rates,
which include Monroe and Davidson County data only, the
principal counties served by the study hospitals.
Population-based annual incidence rates per 100,000 chil-
dren were calculated for a 12-month period, October 2000
through September 2001, by weighting the observed num-
ber of enrolled, hospitalized cases to account for sampling
days per week and nonresponse by age, dividing by the
2000 U.S. Census population count, and multiplying by
100,000. Ninety-five percent confidence intervals (CIs)
were calculated by bootstrap methods (14) 
Results
Six hundred sixty-eight samples were analyzed from
641 children enrolled in the network from August 2000
through September 2001 (27 children were hospitalized
twice and eligible to participate both times). Enrollment by
site was evenly distributed (Table 1), and no differences in
age or sex distributions of the participants were noted
between the sites. However, the Rochester site enrolled
significantly more white non-Hispanic children in the
study than the Nashville site (risk ratio [RR] = 1.3, p =
0.0002), representing differences in overall racial distribu-
tion between the sites. More male patients participated in
the study than female patients, reflecting the higher pro-
portion of ARI hospitalizations for boys (57%), and the
median age of study participants was 6 months (range
<1–59 months). Among the 668 samples, 26 (3.9%) tested
positive for HMPV; 125 (18.7%) tested positive for RSV;
45 (6.7%) tested positive for parainfluenza viruses 1, 2, or
3; and 23 (3.4%) tested positive for influenza virus. 
HMPV Patient Description
The remaining analyses in this section describe the 26
HMPV-positive patients and compare them with the 125
RSV-positive patients and the rest of the cohort (517
patients who were neither HMPV- nor RSV-positive). The
26 HMPV-positive patients were mostly male (18 [69%]),
and 17 (65%) were from the Rochester study site. The
median age of HMPV-positive patients was significantly
higher than that of the RSV-positive patients (11.5 months
and 3 months, respectively; p < 0.0001) and approached
significance when compared to the median age of the rest
of the cohort (11.5 months and 7 months, respectively; p =
0.06). Most of the HMPV-positive patients were 6 months
to 2 years of age compared with an age of <6 months for
most of the RSV-positive patients (p = 0.0015) and the rest
of the cohort (p = 0.0002) (Table 1).
Among the 26 HMPV-positive children, 8 (31%) were
reported to have been born >1 month premature, and 16
(62%) were breastfed. Half of the HMPV-positive children
were exposed to a household smoker, and eight (31%)
attended daycare >4 hours per week. These findings were
not significantly different from those for the RSV-positive
children or the rest of the cohort (Table 1). 
Preexisting medical conditions were assessed both by
parent or guardian interviews and medical record reviews.
Fourteen (54%) HMPV-positive children had serious
underlying medical conditions, compared with 36 (29%) of
RSV-positive children (RR = 2.4, p = 0.01) and 163 (32%)
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Among the 14 HMPV-positive children with underlying
conditions, the most frequently reported conditions were
asthma (8 patients) and heart disease (3 patients). Three
children had more than one condition reported.
HMPV Clinical Description
Admission diagnoses were captured for all patients
enrolled in the study. Pneumonia (6 patients), bronchiolitis
(6 patients), asthma (3 patients), and fever without localiz-
ing signs (3 patients) were the top four admission diag-
noses mentioned for HMPV-positive patients. For
RSV-positive patients, bronchiolitis (54 patients), RSV (47
patients), pneumonia (33 patients), and asthma (20
patients) were the admission diagnoses most frequently
mentioned.
Among the 26 HMPV-positive patients, 24 (92%) had
cough as a symptom. This finding was similar to the per-
centage of RSV-positive patients, but it was a significantly
greater percentage than the 64% of the cohort who experi-
enced cough (RR = 1.7, p = 0.0001). Other predominant
symptoms of HMPV-positive patients included 19 (73%)
with fever, 20 (77%) with nasal congestion, and 21 (81%)
with shortness of breath. During the course of their hospi-
tal stays, HMPV-positive patients tended to be admitted to
intensive care units more than the rest of the cohort (RR =
2.8, p = 0.06), and they were more likely to receive supple-
mental oxygen while hospitalized (RR = 1.8, p = 0.008)
(Table 2). 
Twenty-three (88%) HMPV-positive patients received
chest radiographs during their hospital stay. This percent-
age was similar to 84% of RSV-positive patients who
received chest radiographs but significantly more than the
rest of the cohort, of whom only 59% received chest radi-
ographs (RR = 1.5, p = 0.005). Nine (39%) HMPV-posi-
tive patients had radiologic evidence of pneumonia or
pulmonary infiltration, while 11 (48%) had evidence of
hyperinflation. These percentages were not significantly
different from the RSV-positive patients and the rest of the
cohort (Table 2).
Up to 10 discharge diagnoses were recorded for each
study patient. The most frequently mentioned clinical
diagnoses among all discharge codes for HMPV-positive
patients were asthma (7 patients), pneumonia (6 patients),
bronchiolitis (6 patients), hypovolemia (5 patients), and
otitis media (4 patients). These discharges were similar to
those coded for RSV-positive patients.
Seasonality for HMPV was estimated by using admis-
sion dates for HMPV-positive children. The earliest case
appeared in Rochester on January 1, 2001. The first case in
Nashville appeared 7 weeks later on February 19, 2001.
Though most HMPV cases occurred from January to April
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Table 1. Characteristics of HMPV-positive patients, RSV-positive patients, and the rest of the study cohort, New Vaccine Surveillance 
Network acute respiratory illness study, August 2000–September 2001 
Characteristic  HMPV-positive, n = 26 (%)  RSV-positive, n = 125 (%)  Rest of cohort, n = 517 (%) 
Median age  11.5 mo
a,c  3 mo  7 mo 
Range  1–43 mo  <1–56 mo  <1–59 mo 
Age distribution       
<6 mo  5 (19)
b,c  73 (58)
a,c  244 (47) 
6 mo–1 y  8 (31)
b,c  26 (21)
a,c  80 (15) 
1–2 y  11 (42)
b,c  19 (15)
a,c  82 (16) 
>2 y  2 ( 8)
b,c  7 ( 6)
a,c  111 (22) 
Male  18 (69)  72 (58)  295 (57) 
Race       
White (non-Hispanic)  17 (65)  75 (60)  256 (50) 
Black (non-Hispanic)  8 (31)  32 (26)  172 (33) 
Hispanic  1 ( 4)  13 (10)  55 (11) 
Other  0 ( 0)  5 ( 4)  26 ( 5) 
Unknown  0 ( 0)  0 ( 0)  8 ( 2) 
Underlying medical condition  14 (54)
a,d  36 (29)  163 (31)
b,d 
Born premature  8 (31)  19 (16)  77 (15) 
Breastfed  16 (62)  71 (58)  274 (53) 
Exposed to household smoker  13 (50)  50 (41)  236 (46) 
Attended daycare  8 (31)  31 (25)  167 (32) 
Site       
Nashville  9 (35)  59 (47)  282 (55) 
Rochester  17 (65)  66 (53)  235 (45) 
aComparison of HMPV-positive to RSV-positive patients. HMPV, human metapneumovirus; RSV, respiratory syncytial virus. 
bComparison of HMPV-positive patients to rest of cohort. 
cp < 0.001. 
dp < 0.05. 2001, Nashville identified one case each in May and in
August (Figure).
HMPV Population-based Hospitalization Rates
To estimate population-based hospitalization rates, we
focused only on cases that resided in Davidson and
Monroe Counties. Of the 26 HMPV-positive cases, 19
(73%) resided in these two counties, 9 in Davidson County
and 10 in Monroe County. Adjusted for age, the estimated
hospitalization rates per 100,000 persons for HMPV infec-
tion were 114 cases (95% CI 47 to 198) for children <12
months of age, 131 cases (95% CI 51 to 225) for children
1–2 years of age, and 10 cases (95% CI 0 to 20) for chil-
dren 2–5 years of age.
Discussion
These data suggest that among children <5 years of age
hospitalized with respiratory illness, HMPV is associated
with a rate of community-acquired ARI similar to that of
the combined parainfluenza viruses 1–3 and influenza
viruses but substantially less than that associated with
RSV. The incidence of 3.9% of positive HMPV specimens
among those tested is slightly greater than the 2.3% report-
ed in one Canadian study (10) and slightly less than the
5.5% reported in a Hong Kong study (8) of similar design.
Other studies have found that HMPV incidence can vary
from year to year, sometimes rivaling or exceeding RSV
incidence (13,15). Our single year of data did not allow us
to evaluate this.
As reported in other HMPV studies, clinical symptoms
of HMPV-positive patients mirrored those of RSV-positive
patients. While this comparison could indicate that HMPV
may be associated with a similarly severe respiratory ill-
ness such as RSV, the clinical care information is more
revealing. The tendency for HMPV-positive patients to be
admitted to the intensive care unit and their increased
requirement for supplemental oxygen during their hospital
stay occurred with similar frequency to RSV-positive
patients (Table 2). Therefore, while the incidence of
HMPV infection may not compare with that of RSV infec-
tion, the disease severity may be very similar. 
The observed illness severity could have been influ-
enced by underlying medical conditions reported in half of
HMPV-positive patients. Indeed, three of four HMPV-pos-
itive children admitted to the ICU and 8 of 14 requiring
supplemental oxygen had underlying medical conditions.
However, proportions of underlying medical conditions
were not significantly different for RSV-positive patients
or the rest of the cohort that required these same hospital
services. 
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Table 2. Clinical characteristics of HMPV-positive patients compared with RSV-positive patients and the rest of the study cohort, New 
Vaccine Surveillance Network acute respiratory illness study, August 2000–September 2001
a 
  HMPV-positive, n = 26  RSV-positive, n = 125  Rest of cohort, n = 517 
Clinical characteristic  n (%)  n (%)  n (%) 
Presenting symptoms       
Cough  24 (92)
b,c  124 (99)  333 (64) 
Fever  19 (73)  85 (68)  383 (74) 
Nasal congestion  20 (77)  110 (88)  329 (64) 
Shortness of breath  21 (81)  119 (95)  334 (65) 
Hospital course       
Admitted to intensive care unit  4 (15)  6 ( 5)  28 ( 5) 
Received supplemental O2  14 (54)
b,d  76(61)  51 (29) 
Intubated  2 ( 8)  3 (2)  10 (2) 
Chest x-ray findings  (n = 23)  (n = 105)  (n = 304) 
Chest x-ray performed  23 (88)
b,d  105 (84)  304 (59) 
Any pneumonia/infiltration  9 (39)  25 (23)  77 (25) 
Hyperinflation  11 (48)  54 (51)  103 (34) 
aHMPV, metapneumovirus; RSV, respiratory syncytial virus. 
bComparison of HMPV-positive patients to rest of cohort.  
cp < 0.001. 
dp < 0.01. 
Figure. Distribution of HMPV patients and overall study admis-
sions by month of admission, New Vaccine Surveillance Network
acute respiratory illness study, Aug 2000–Sept 2001. Black bars
represent HMPV-positive patients, while the line represents study
admissions.Asthma was the most frequently recorded discharge
diagnosis among HMPV-positive children. A review of
individual cases showed that six of the seven HMPV-posi-
tive children with asthma as a discharge diagnosis also had
asthma as an underlying medical condition. Two of these
children were specifically diagnosed with acute exacerba-
tion of asthma. This finding is similar to findings from a
recent HMPV study in Finland that suggested HMPV may
stimulate asthmatic episodes in children with asthma (7),
but it contrasts findings from an Australian study that
showed no such association (16).
Our study found that HMPV-infected children were sig-
nificantly older (median age 11.5 months) than RSV-posi-
tive children (median age 3 months) (Table 1). This age
difference was also noted in the Hong Kong study (8), and
our median age for RSV-positive patients is consistent with
previous reports (17). With other clinical aspects of HMPV
infection so similar to RSV, one might have expected the
age distribution of HMPV-positive patients to be similar as
well. The difference could be due to longer lasting maternal
immunity to HMPV compared with RSV, or perhaps the
pathogenesis of HMPV disease favors older children. More
research is needed to answer these questions. 
Our year-round surveillance for respiratory illness
showed that HMPV infection tended to occur mainly dur-
ing the winter months, much like influenza virus and
RSV. This finding was also observed in other HMPV
studies, though sampling only occurred during the winter
months in those studies (1,4,6,9). The identification of
HMPV-positive children in May and August, however,
suggests that HMPV may continue to circulate in the
spring, as was observed in a previous study (13), or pos-
sibly year-round.
In the United States, outbreaks of RSV disease tend to
occur in the southern United States several weeks before
the northeastern United States (18). In this study, HMPV
infections were first identified in Rochester 7 weeks before
the first infections in Nashville (data not shown). This
finding may indicate that HMPV circulation does not
exhibit the same pattern of activity as RSV, but our small
number of HMPV-positive patients and 1 year of data limit
our conclusions. Multiple years of surveillance, encom-
passing a wide geographic area, are needed to verify this
preliminary observation.
Our study is subject to several limitations. The use of
combined nose and throat swab specimens, as opposed to
nasopharyngeal aspirate specimens, may have resulted in a
substantial number of false-negative results. In particular,
RSV detection seems to vary substantially by the type of
specimen collected (19,20). Whether HMPVdetection also
varies by specimen type in a similar manner is unknown.
Similarly, the use of frozen aliquots of specimens shipped
in lysis buffer may have decreased virus yield somewhat
for all the pathogens tested. We may have detected viral
RNA from an earlier acute infection but not directly asso-
ciated with the study illness. The amount and duration of
shedding of HMPV has not been well described. Finally,
the small number of positive HMPV patients limits our
ability to fully characterize features of HMPV infection.
Nevertheless, our data suggest that HMPV infection is
associated with severe respiratory illness in children.
Further study is now needed to fully explore the link
between disease and infection, assess seasonality patterns
and incidence of disease, and examine risk factors for
severe disease with infection. 
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